Samuel J. Asirvatham, M.D., is an electrophysiologist at Mayo Clinic's campus in Rochester, Minnesota. After completing medical school at the Christian Medical College in Vellore, India, his internship was at the Columbia University Medical Center in New York City.
Following residency and chief residency at the University of Wisconsin-Madison, he did his clinical cardiac and electrophysiology training at the University of Oklahoma near Oklahoma City.
Dr. Asirvatham is currently a professor of medicine in the Division of Cardiovascular Diseases within the Department of Internal Medicine and a professor of pediatrics in the Division of Pediatric Cardiology within the Department of Pediatric and Adolescent Medicine. He is a consultant in cardiac electrophysiology.
He is also program director for the Clinical Cardiac Electrophysiology Fellowship and director of strategic collaboration for the Center for Innovation at Mayo Clinic, Rochester, Minnesota.
Dr. Asirvatham's research and innovation interests include:
- Development of a percutaneous epicardial system to close the left atrial appendage
- Renal nerve stimulation for the treatment of neurocardiogenic syncope
- Development of a novel circuit to prevent coagulum formation during radiofrequency ablation procedures
- Specifically designed and created tools to allow electrophysiology mapping and ablation through the veins of the central nervous system to treat seizures and other central nervous system disorders
Significance to patient care
One of the primary goals of Dr. Asirvatham's clinical research is improving quality of life and patient care.
Current research projects include solutions to neurocardiogenic syncope by utilizing pacing in the renal vein to increase blood pressure and prevent syncope; epilepsy and other central nervous system disorders by mapping and ablation of the central nervous system; and stroke and thromboembolic events in atrial fibrillation patients and atrial fibrillation patients after ablation through left atrial ligation/obliteration and coagulum reduction, and investigating the possible link of stroke events with cardiac device leads.